topleft
topright

Want This Page Wider?

Use the A+, A-, R, and <> or <-> buttons at the top right of this page to make the fonts bigger and smaller or switch between a fixed-width and fluid-width style to this web site.
Defense Grant for Traumatic Brain Injury Pain Study PDF Print E-mail
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program (DMRDP), an agency of the U.S. Department of Defense (DoD). This grant will support the study of Lpathomab for the treatment of neuropathic pain associated with traumatic brain injury (TBI). Lpath is working with Professor David Yeomans, Ph.D. of Stanford University's Department of Anesthesia on this project and he will serve as co-principal investigator.

This DoD grant will fund preclinical studies designed to evaluate the ability of Lpathomab to alleviate pain following neurotrauma, and to confirm the potential efficacy of Lpathomab as previously demonstrated by Stanford University researchers in an animal model of TBI pain.

Roger Sabbadini, Ph.D., Lpath's founder and co-principal investigator on the TBI project, commented, "Lpath is grateful to the DoD for recognizing the significant value of funding further development of Lpathomab. We believe our novel approach of targeting bioactive lipids holds great promise, and this is validated by the financial commitment from the DoD's DMRDP."

Lpath has recently completed a Phase 1a double-blind, placebo-controlled, single ascending dose study to evaluate the safety and tolerability of Lpathomab in healthy volunteers. Lpathomab was tolerated at all doses tested, and no serious adverse events or dose limiting toxicities were observed.

Dario Paggiarino, M.D., Lpath's senior vice president and chief development officer commented, "Now that Lpath has successfully demonstrated safety and tolerability of Lpathomab in healthy volunteers, we anticipate testing Lpathomab in patients with neuropathic pain. The preclinical demonstration of Lpathomab's potential efficacy in TBI pain could support another important indication for further investigation."
 
< Prev   Next >

West-Point.Org (WP-ORG), a 501(c)(3) non-profit organization not affiliated officially with the United States Military Academy, provides an online communications infrastructure that enables graduates, parents, and friends of the military academy to maintain and strengthen the associations that bind us together. We will provide this community any requested support, consistent with this purpose, as quickly and efficiently as possible. WP-ORG is funded by the generosity of member contributions. Our communication services are provided in cooperation with the AOG (independent of USMA) and are operated by volunteers serving the Long Gray Line. Contents of and comments on this web site do not reflect the official position of the United States Military Academy or the Department of the Army.  For questions or comments, please email us at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Joomla Template by Joomlashack
Joomla Templates by JoomlaShack Joomla Templates